AtStaff (Seattle) has introduced the new ClairVia software, ClairVia eWork, which it says facilitates access to external staff while optimizing safety standards, quality and cost control of supplemental employees. By using ClairVia eWork, healthcare organizations and external labor firms interact together to automate the selection, approval, and deployment of qualified, cost-effective supplemental staff, and coordinate billing. ClairVia eWork integrates with other ClairVia solutions, which assist safety standards, quality and cost control of all internal staffing resources, to provide a total, end-to-end solution for automating "time to fill" of all staffing needs — whether they're from internal or external sources. AtStaff makes healthcare management software.

Fluidigm (South San Francisco, California) reported the availability of its new BioMark IFC controller MX, part of the company's system for high-throughput genetic analysis. The BioMark IFC controller MX is targeted for set up of high-throughput gene expression, genotyping, and digital PCR experiments. It features a menu for automatically loading BioMark 48.48 dynamic arrays and 12.765 digital arrays. The IFC includes built-in software and a self-contained gas source for pressure-loading samples and assays into the dynamic arrays and digital arrays. The BioMark system is a combination of integrated fluidic circuit chips, instrumentation and applications software. Fluidigm makes integrated fluidic circuit systems.

Osteotech (Eatontown, New Jersey) said it has received FDA clearance for the Plexur P biocomposite for use in spinal applications as a bone void filler and as a bone graft extender. Previously, Osteotech received FDA clearance for Plexur P for use in filling bony voids of the pelvis and extremities. The Plexur uses bone tissue for procedure specific surgical applications in combination with a wide variety of polymers. The Plexur P biocomposite has been used by surgeons in tibial plateau fractures, tibial osteotomies and a variety of foot and ankle procedures, and can now be used in the spine. Osteotech specializes in regenerative medicine.

Terumo Heart (Ann Arbor, Michigan) made a presentation titled "Long-Term Circulatory Support with the DuraHeart Mag-Lev Centrifugal LVAS for Advanced Heart Failure Patients Eligible for Transplantation: European Experience" at the recent International Society for Heart & Lung Transplantation (Addison, Texas) meeting in Boston. The presentation concluded that Terumo's DuraHeart LVAS provides safe and reliable long-term circulatory support with improved survival. The DuraHeart is a circulatory support device intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. Terumo Heart specializes in making heart failure devices.